Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial

Bradley J. Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M. Provencher, Beth Y. Karlan, Catherine Lhommé, Gary Richardson, Dolores Gallardo Rincón, Robert L. Coleman, Thomas J. Herzog, Christian Marth, Arija Brize, Michel Fabbro, Andrés Redondo, Aristotelis BamiasMarjan Tassoudji, Lynn Navale, Douglas J. Warner, Amit M. Oza

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)661-662
Number of pages2
JournalObstetrical and Gynecological Survey
Volume69
Issue number11
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D. S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., Lhommé, C., Richardson, G., Rincón, D. G., Coleman, R. L., Herzog, T. J., Marth, C., Brize, A., Fabbro, M., Redondo, A., ... Oza, A. M. (2014). Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Obstetrical and Gynecological Survey, 69(11), 661-662.